Liminal Biosciences Profit Margin

Liminal Biosciences posts a profit margin of 71.95% as of June 2023. That compares with 9107.96% in the prior-year period — down 99.2% year over year. That is above the Healthcare sector average of 13.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Liminal Biosciences's profit margin was 9107.96%. The latest reading is 71.95% — a 99.2% year-over-year decrease (period ending June 2023). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 13.89% is typical. Liminal Biosciences's 71.95% is higher that level. That is roughly 418.0% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Liminal Biosciences's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 71.95% as of June 2023; use YoY and peer views to separate noise from signal.

Context for LMNL's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.89%), and (3) consistency with growth and profitability. This page covers the first two; Liminal Biosciences's other metric pages and overview cover the third.